Martha Mims, MD
Hematology & Oncology · Houston, TXNPI 1295954147
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.6% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Novartis at 59.9% of the total. Reporting peaked in 2019 at $112 and has fallen 74.5% since, to $29 in 2025. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 9 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$111
- Eisai Inc.$29
- Pfizer$21
- Bristol Myers Squibb$13
- Gilead$12
Across 63 payments — averaging $5879.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$223K
- Incyte Corporation$81K
- Bristol Myers Squibb$58K
- E.r. Squibb & Sons, L.L.C.$6K
- AVEO Pharmaceuticals, Inc.$2K
What the payments were for
- Food & beverage$17494%
- Education$126%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $111 |
| Eisai Inc. | 1 | $29 |
| Pfizer | 1 | $21 |
| Bristol Myers Squibb | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$186 in reported general payments places this provider in the 10th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 26 | $432,209 |
| CabometyxCabozantinib S-Malate | 17 | $420,128 |
| XtandiEnzalutamide | 19 | $255,676 |
| BrukinsaZanubrutinib | 11 | $169,041 |
| Abiraterone Acetate | 78 | $123,354 |
| Imatinib Mesylate | 25 | $8,408 |
| Hydroxyurea | 29 | $802 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 44 | $478 |
| Prednisone | 55 | $303 |
| Dexamethasone | 20 | $251 |
| Acyclovir | 17 | $174 |
| Ondansetron Hcl | 13 | $145 |
| Tramadol Hcl | 13 | $21 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.